Thomas Heydler appointed to the Supervisory Board of Eppendorf AG

Hamburg, Germany, February 21, 2019 - Thomas Heydler has been a member of the Supervisory Board of Eppendorf AG since January 25, 2019. He succeeds Dr. Michael Schroeder, who resigned for personal reasons. "With Thomas Heydler, we have succeeded in gaining another very experienced manager for the Eppendorf Supervisory Board. We are looking forward to this and to working with him", says Philipp von Loeper, Chairman of the Supervisory Board of Eppendorf AG. "We are confident that he will enrich the work of our Supervisory Board with his many years of international experience as CEO and his outstanding entrepreneurial competence." Thomas Heydler has been CEO of Definiens AG, Munich, Germany, a specialized software and solution provider in the pharmaceutical industry, since 2004. Previously, he was CEO and Managing Director of various software companies in Germany and the USA. Thomas Heydler has more than 30 years of entrepreneurial expertise and a deep understanding of the global software business in the pharmaceutical and life science industries.

About Eppendorf AG

Eppendorf is a leading life science company that develops and sells instruments, consumables and services for liquid handling, sample handling and cell handling in laboratories worldwide. Its product range includes pipettes and automated pipetting systems, dispensers, centrifuges, mixers, spectrometers and DNA amplification equipment as well as ultra-low temperature freezers, fermentors, bioreactors, CO2 incubators, shakers and cell manipulation systems. Consumables such as pipette tips, test tubes, microliter plates, and single-use bioreactor vessels complement the range of highest-quality premium products. Eppendorf products are most broadly used in academic and commercial research laboratories, e.g., in companies from the pharmaceutical and biotechnological as well as the chemical and food industries. They are also aimed at clinical and environmental analysis laboratories, forensics and at industrial laboratories performing process analysis, production and quality assurance. Eppendorf was founded in Hamburg, Germany in 1945 and has more than 3,100 employees worldwide. The company has subsidiaries in 26 countries and is represented in all important markets by distributors.

Source: Eppendorf AG Press Release from February 22th, 2019,
https://corporate.eppendorf.com/en/news-media/newsroom/?layer=/en/press-releases/21022019-thomas-heydler-appointed-to-the-supervisory-board-of-eppendorf-ag/

More News

GQ Bio is pioneering a high-capacity adenovirus (HCAd) gene therapy vector platform that addresses some of the big challenges in the gene therapy field. (Picture: GQ Bio)
GQ Bio is pioneering a high-capacity adenovirus (HCAd) gene therapy vector platform that addresses some of the big challenges in the gene therapy field. (Picture: GQ Bio)

Pacira BioSciences Acquires GQ Bio

HTGF portfolio company GQ Bio, pioneering a high-capacity adenovirus gene therapy vector platform, was acquired by Pacira BioSciences, Inc. Pacira, the industry leader in its ...

Read more …
At its new premises in the tecHHub Hamburg, CrystalsFirst is significantly expanding its operations to foster greater synergy. (Picture: CrystalsFirst)
At its new premises in the tecHHub Hamburg, CrystalsFirst is significantly expanding its operations to foster greater synergy. (Picture: CrystalsFirst)

CrystalsFirst Scales Operations...

CrystalsFirst, a leading provider of advanced structural biology solutions and AI-driven drug discovery, is pleased to announce a multi-million-euro expansion of its laboratory infrastructure and ...

Read more …
medac has received FDA approval for treosulfan (Copyright Adobe Stock - Nicolas Hermbach)

Strategic cornerstone for medac: FDA approves treosulfan for alloHSCT

medac has received FDA approval for treosulfan as a new drug application with orphan drug designation prior to allogeneic hematopoietic stem cell transplantation (alloHSCT) in ...

Read more …